Go back

Sanofi to buy Sanger Institute spin-out in £1bn deal

Image: Kymab

Wellcome-backed Kymab snapped up by French biotech company

Biotech giant Sanofi is to buy Cambridge-based company Kymab in a deal potentially worth over £1 billion.

In 2010, Kymab became the first spin-out company to emerge from the UK’s lauded Wellcome Trust Sanger Institute, based on work by Sanger researcher Allan Bradley and funded initially by $30 million (£22m) from the Wellcome Trust Investment Division.

This article is only available to *Research Professional subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Alternatively, Pivot-RP users can log in and view the article via this link.